JoAnn V. Pinkerton, MD

Nearly half of menopausal sleep disruption tracks with nighttime hot flashes, while the remainder appears independent, making nocturnal fragmentation a distinct clinical target rather than a secondary effect.

Sleep disturbance is often the most bothersome symptom of the menopause transition, yet it frequently goes unreported unless clinicians ask directly about sleep quality and daytime fatigue.

JoAnn V. Pinkerton, MD, offers primary care counseling on elinzanetant's side effects and the early onset and continued relief of hot flashes.

JoAnn V. Pinkerton, MD, MSCP, reviews 4 pooled elinzanetant analyses from OASIS presented at The Menopause Society Annual Meeting 2026, spanning late perimenopause, sleep, VMS reduction, and safety.

Experts highlight future research in personalized menopause care, exploring hormone safety, the microbiome, cognition, and metabolic health.

Experts compare hormone and nonhormonal options for menopause, emphasizing tailored care, persistent symptom relief, and safe use of local estrogen.

Experts discuss how neurokinin receptor antagonists offer rapid, durable, and nonhormonal relief for vasomotor symptoms, reshaping menopause care.

Experts discuss neurokinin receptor drugs, CBT, and lifestyle tools for managing vasomotor symptoms, emphasizing innovation and evidence-based care.

Experts discuss contraindications to hormone therapy and evolving care for women with early or surgical menopause, emphasizing individualized treatment.

Experts review updated VMS treatment guidelines and stress shared decision-making to personalize hormone and nonhormone therapy options.

Experts emphasize normalizing menopause discussions early to reduce stigma and improve communication in both clinical and workplace settings.

Experts discuss how culture, stigma, and inequities shape menopause care and leave many women without adequate symptom management.

Experts highlight education, equity, and access gaps in vasomotor symptom care, calling for stronger clinician training and awareness.

Experts discuss updates in the management of vasomotor symtpoms in menopause, including unmet needs, quality of life impacts, and new therapies.

In the 52-week OASIS-3 trial, elinzanetant significantly reduced the frequency and severity of hot flashes and night sweats.

Postmenopausal osteoporosis is a major health problem, primarily because of the severe morbidity and mortality associated with osteoporotic fractures.